Gabapentin for acute pain in sickle cell disease: A randomized double-blinded placebo-controlled phase II clinical trial

Latika Puri¹,⁵ | Kerri Nottage² | Jane S. Hankins¹ | Winfred C. Wang¹ | Olivia McGregor¹ | Jeffrey M. Gossett³ | Guolian Kang³ | Doralina L. Anghelescu⁴

¹ Department of Hematology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
² Janssen Research and Development, Raritan, New Jersey, USA
³ Department of Biostatistics, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
⁴ Division of Anesthesia, Department of Pediatric Medicine, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
⁵ Division of Hematologic/Oncologic Therapeutics, Department of Pediatrics, Loma Linda University Children’s Hospital, Loma Linda, California, USA

Correspondence
Doralina L. Anghelescu, Division of Anesthesia, Department of Pediatric Medicine, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Mail Stop 130, Memphis, TN 38105-3678, USA.
Email: doralina.anghelescu@stjude.org

Abstract
Pain in sickle cell disease (SCD) can have a neuropathic component. This randomized phase II double-blinded placebo-controlled study evaluated the efficacy of gabapentin in reducing pain and opioid consumption (morphine-equivalent dose [MED]) during acute vaso-occlusive crisis (VOC). Of 90 patients aged 1–18 years with VOC pain, 45 were randomized to a single gabapentin dose (15 mg/kg) and 45 to placebo, in addition to standard treatment; 42 and 44 patients were evaluable in the gabapentin and placebo arms, respectively. A decrease in pain of $\geq 33\%$ was reported in 68% of patients in the gabapentin arm and 60% of those in the placebo arm ($p = 0.23$). The median MED (mg/kg) in the gabapentin (0.12) and placebo arms (0.13) was similar ($p = 0.9$). However, in the subset of patients with the HbSS genotype ($n = 45$), the mean (SD) absolute pain score decrease by the time of discharge was significantly greater in the gabapentin arm (5.9 [3.5]) than in the placebo arm (3.6 [3.3]) ($p = 0.032$). Pain scores in the overall study population were not significantly reduced when gabapentin was added to standard treatment; however, gabapentin benefited individuals with the more severe genotype, HbSS, during acute VOC. Larger, prospective studies are needed to confirm these findings.

KEYWORDS
Gabapentin, neuropathic pain, randomized controlled trial, sickle cell disease

1 | INTRODUCTION

Acute vaso-occlusive crisis (VOC) is the hallmark of sickle cell disease (SCD) and continues to be the most common cause of emergency room visits and hospitalizations in patients with SCD [1]. These pain crises increase in frequency, duration, and intensity with age [1]. Pain in SCD is typically considered nociceptive because of mechanisms of vaso-occlusion, subsequent tissue ischemia, and inflammation [2,3]. However, studies in mice with SCD implicate neuropathic pain mechanisms [4–8]. Additionally, patient-reported outcome studies using neuropathic pain questionnaires suggest that 40% of adult patients with SCD endorse pain descriptors typically used by patients with known sources of neuropathic pain [3,9–11]. Quantitative sensory testing studies in patients with SCD suggest both peripheral and central nervous system sensitization, whereas functional MRI findings suggest the presence of central nervous system abnormalities [9,12–15]. These data suggest a complex etiology of SCD pain, including ischemic, inflammatory, and neuropathic components. However, therapies
targeting neuropathic pain in SCD have not been prospectively studied in the setting of acute pain crises.

The backbone of treatment of acute pain crisis has been intravenous opioids. Patients with SCD often require large opioid doses because of increased opioid metabolism and clearance [16], as well as tolerance from receiving long-term opioid therapy, leading to pain that may become increasingly refractory to opioids [2].

Gabapentin has been used successfully to treat neuropathic pain in various clinical settings, including complex regional pain syndromes, diabetic neuropathy, and postherpetic neuralgia [17–19]. Additionally, it has proven opioid-sparing effects in the acute pain postoperative setting in adults [20,21] and children [22].

Gabapentinoids bind to presynaptic neurons at the alpha2-delta subunit of voltage-gated calcium channels and reduce calcium influx into presynaptic terminals and therefore reduce excessive release of excitatory neurotransmitters (e.g., glutamate, substance P, and noradrenaline); their effects on central sensitization and hyperalgesia are indirect rather than direct [23,24]. Gabapentin and morphine may be synergistic because they act on independent targets within the peripheral and central nervous systems [25]. The mechanism for reducing central sensitization is reduction of hyperexcitability of secondary nociceptive neurons in the dorsal horn by suppressing the release of excitatory amino acids in the spinal cord in response to noxious stimuli [26]. In children, evidence for gabapentin use has been limited to case reports [27] and retrospective case series [28–30]; therefore, formally testing gabapentin in a prospective randomized study is warranted.

This randomized phase II double-blinded placebo-controlled study tested the hypothesis that gabapentin (in comparison to placebo) used in addition to standard treatment during an acute VOC in children with SCD would (1) reduce pain scores and (2) reduce opioid consumption.

2 | PATIENTS AND METHODS

2.1 | Enrollment and patient population characteristics

This randomized phase II double-blinded placebo-controlled trial was conducted at St. Jude Children’s Research Hospital after approval by the Institutional Review Board (IRB). An Investigational New Drug approval (IND119125) was issued by the Food and Drug Administration. The study was registered at clinicaltrials.gov (NCT01954927). All authors had access to primary clinical trial data. The data analysis was performed by Jeffrey M Gossett and Guolian Kang. A full description of the study’s methodology has been published [31]. Children and young adults between 1 and 18 years of age, with SCD (any genotype), who presented with VOC with a pain score >4, and required intravenous opioids but lacked other acute complications, such as acute chest syndrome or splenic sequestration, were eligible to participate. Patients were excluded for pain scores ≤4, renal dysfunction (GFR < 60 mL/min/1.73 m²), a history of seizures, current pregnancy or breastfeeding, or treatment with gabapentinoid or other anti-epileptic drugs.

Patients were enrolled and randomized to receive either a single oral dose of gabapentin (15 mg/kg) or a similarly formulated dose of placebo in addition to standard treatment for VOC as per our institutional St. Jude Sickle Cell Disease Pain Management Guidelines. Standard treatment for acute VOC in patients at our institution includes intravenous hydration and analgesic management with nonsteroidal anti-inflammatory drugs (ketorolac) and opioids (morphine or hydromorphone). In the acute care outpatient clinic, opioids are usually administered in a structured fashion (e.g., morphine 0.05–0.1 mg/kg, every 30 min as needed based on pain score, and the dose is titrated as clinically indicated, as presented in the supplemental material). For analysis, all opioid doses were converted to intravenous morphine equivalent doses (mg/kg) by opioid equianalgesic potency. The following ratios were used: fentanyl:morphine, 100:1; hydromorphone: morphine, 5:1 [32].

2.2 | Clinical trial data sharing

Deidentified participant data and study protocol will be available beginning 9 months and ending 36 months following article publication. These data will be available to investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose. Requests should be directed to the corresponding author; to gain access, data requestors will need to sign a data access agreement.

2.3 | Primary outcome: pain score reduction

The primary endpoint was defined as a ≥33% decline in pain score between baseline and assessment at 3 h poststudy drug administration. Pain scores were collected at four time points: T₀, baseline (i.e., presentation to the acute care setting); T₁, at the time of study drug administration; T₂, 3 h post study drug administration; and T₃, at the time of decision for disposition from the acute care setting either to discharge home or to admission to the hospital (Figure 1). Pain scores were documented in the electronic medical record. Pain was measured by using validated age-appropriate pain scales: the FLACC (Faces, Legs, Arms, Cry, and Consolability) scale for children younger than 4 years [33]; the FACES scale for children aged from 4 to 7 years [34]; and the numeric rating scale for children older than 7 years [35,36]. We analyzed the differences between the pain score at baseline (T₀) and that at each of the other time points (T₁, T₂, T₃). Pain score outcomes were examined for the overall study group.

2.4 | Secondary outcome: opioid consumption

The opioid consumption in morphine-equivalent dose (MED) during the duration of VOC from presentation (T₀) to 3 h post-study drug administration (T₂) in the gabapentin group was compared with that in the placebo group.
2.5 Exploratory outcome: admission rates

Admission rates were examined in the two treatment arms. All outcomes were examined for the overall study group and the subgroup of patients with the HbSS genotype.

2.6 Statistical analysis

The study was designed to have no more than a 5% chance ($\alpha = 0.05$) of falsely concluding that adding gabapentin to standard treatment increases the proportion of patients with a decrease in pain score when there is no difference between gabapentin and placebo groups. Continuous variables were summarized as mean (standard deviation) or median (interquartile range). Categorical variables were summarized by the percentage of frequency. Continuous variables were compared by using either two-group $t$-tests or the non-parametric Wilcoxon/Mann-Whitney tests, depending on the result of the Shapiro-Wilks test of normality. Categorical variables were compared by using either Pearson's chi-square or Fisher's exact test. Two-sided tests were used for all comparisons other than the primary hypothesis. The primary outcome, a 33% decrease of pain score from presentation ($T_0$) to 3 h after study drug administration ($T_2$), was analyzed by using a right-tailed (i.e., one-sided) $z$-test for proportions.

Statistical analyses were performed by using SAS software, version 9.4 (SAS Institute, Cary, NC) and RStudio (RStudio Team (2018); RStudio: Integrated Development for R. RStudio, Inc., Boston, MA) with R version 3.5.2 (R Core Team, Vienna, Austria). A $p$-value < 0.05 was considered statistically significant.
TABLE 1 Baseline demographics of study participants

| Characteristic                  | All N = 86 | Gabapentin arm N = 42 | Placebo arm N = 44 | p-value |
|--------------------------------|------------|-----------------------|--------------------|---------|
| Age, mean (SD), year           | 11.8 (4.9) | 11.8 (4.5)            | 11.8 (5.3)         | 0.77    |
| Median (IQR)                   | 12.4 (8.1, 15.8) | 11.9 (8.2, 15.6) | 14.3 (7.7, 16.3) |         |
| Sex, n (%)                     | 0.07       |                      |                    |         |
| Male                           | 51 (59.3%) | 29 (69.0%)            | 22 (50.0%)         |         |
| Female                         | 35 (40.7%) | 13 (31.0%)            | 22 (50.0%)         |         |
| Sickle cell genotype, n (%)    |            |                      | 0.019              |         |
| HbSS                           | 44 (51.2%) | 18 (42.9%)            | 26 (59.1%)         |         |
| HbSC                           | 25 (29.1%) | 10 (23.8%)            | 15 (34.1%)         |         |
| HbS/β-thalassemia              | 8 (9.3%)   | 6 (14.3%)             | 2 (4.5%)           |         |
| Other                          | 9 (10.5%)  | 8 (19.0%)             | 1 (2.3%)           |         |
| Pain score on presentation     | 0.77       |                      |                    |         |
| Mean (SD)                      | 7.8 (1.8)  | 8.0 (1.6)             | 7.7 (1.9)          |         |
| Median (IQR)                   | 8 (7.10)   | 8 (7.10)              | 8 (6.5, 10)        |         |

Abbreviation: IQR, interquartile range.

3 | RESULTS

3.1 | Enrollment and patient population characteristics

The accrual goal was 166 patients, with interim analysis planned after half of the patients were enrolled. The results presented are from the interim analysis, with a total of 90 patients enrolled over 56 months (10/2013–05/2018). According to the study design, based on the interim analysis, the study was closed due to clinical futility based on lack of significant results of the primary pain score outcome.

Participants’ demographics are summarized in Table 1. The mean (SD) age was 11.8 (4.9) years (range: 1.9–18.6 years). Gender distribution was similar in the two arms. HbSS was the predominant genotype in both groups. Forty-five patients were randomized to each arm. Three patients in the gabapentin group were excluded from the analysis (one refused participation after consent and randomization; another refused to take the medicine due to unpalatability, and one patient’s pain was determined to be caused by something other than VOC following consent and randomization). In the placebo group, one patient was excluded from analysis because the study drug arrived late, outside the time window allowed by the study design. Eighty-six participants were evaluable: 42 in the gabapentin group and 44 in the placebo group (Figure 2). The power to detect the increase in the proportion of participants with ≥33% reduction in pain scores from 45% to 65% at a level of p-value of 0.05 was 58%. This was based on a one-sided two-sample test for 90 patients (45 in each arm).

3.2 | Pain score reduction

Pain scores at presentation were similar for each group (p = 0.77), with a median (interquartile range [IQR]) of 8 (7–10) in the gabapentin arm and 8 (6.5–10) in the placebo arm. The primary outcome (i.e., ≥33% reduction in pain scores from T0 to T2) was achieved in 67.5% (27/40) of patients in the gabapentin arm and 59.5% (25/42) of patients in the placebo arm (one-sided p = 0.23, Table 2). A favorable response (≥33% reduction in pain scores) from presentation (T0) to discharge from the acute care setting (T3) was noted in 75% (30 of 40) of patients in the gabapentin arm and 61.4% (27 of 44) in the placebo arm (p = 0.18) (Table 2). The absolute decrease in pain score from baseline (T0) to 3 h post-treatment (T2) was not significantly different in the two arms (p = 0.25), and the median (IQR) decrease was 4.0 (1.5–7.0) in the gabapentin arm and 3.0 (1.0–6.0) in the placebo arm.

We performed a sub-analysis of participants with the most severe sickle genotype, HbSS. Although the proportion of patients with HbSS in whom the primary endpoint was achieved was higher in the gabapentin arm than in the placebo arm (76.5% [13 of 17] in HbSS and 61.5% [16 of 26] in the placebo arm), the difference was not statistically significant (p = 0.31) (Table 3). The absolute decrease in pain score of HbSS participants from presentation (T0) to 3 h poststudy drug administration (T2) was not significantly different between treatment arms but may suggest a trend, with mean (SD) pain score decrease of 5.5 (3.4) and 3.6 (3.1) in gabapentin and placebo arms, respectively (p = 0.061). Importantly, the mean (SD) absolute decrease in pain score from presentation (T0) to discharge from the acute care setting (T3) was significantly higher in the gabapentin group (5.9 [3.5]) than in the placebo group (3.6 [3.3]) (p = 0.032).
3.3 | Opioid consumption

Opioid consumption, as measured by MED (mg/kg), from presentation \((T_0)\) to 3 h poststudy drug administration \((T_2)\) was similar between the two treatment groups \((p = 0.90)\). The median (IQR) MED was 0.12 mg/kg \((0.09–0.22\) mg/kg) in the gabapentin arm and 0.13 mg/kg \((0.09–0.22\) mg/kg) in the placebo arm. Likewise, MED for the HbSS subgroup did not differ significantly between treatment arms, with a median (IQR) MED of 0.11 mg/kg \((0.09–0.23\) mg/kg) in the gabapentin arm and 0.12 mg/kg \((0.08–0.23\) mg/kg) in the placebo arm \((p = 0.93)\).

3.4 | Admission rates

As an exploratory objective, we evaluated admission rates in the study arms. A similar number of patients in each group were hospitalized for further pain management: 24% \((10\ of\ 42)\) in the gabapentin arm and 27.3% \((12\ of\ 44)\) in the placebo arm \((p = 0.71)\). In the HbSS genotype subgroup, 34.6% of patients \((9\ of\ 26)\) in the placebo arm and 11.1% of patients \((2\ of\ 18)\) in the gabapentin arm were admitted \((p = 0.16)\) (Table S2).
### TABLE 3 Pain reduction in HbSS subgroup

| Pain response | Gabapentin arm N = 17 | Placebo arm N = 26 | p-value |
|---------------|-----------------------|--------------------|---------|
| ≥33% reduction in pain scores from baseline to 3 h posttreatment | 76.5% (13/17) | 61.5% (16/26) | 0.31 |
| ≥33% reduction in pain scores from baseline to disposition from the acute care clinic | 88.2% (15/17) | 61.5% (16/26) | 0.085 |
| Decrease in pain score from baseline to 3 h posttreatment | | | 0.061 |
| N | 17 | 26 | |
| Mean (SD) | 5.5 (3.4) | 3.6 (3.1) | |
| Median (IQR) | 6.0 (4.0, 8.0) | 3.0 (1.0, 5.0) | |
| Decrease in pain score from baseline to disposition from acute care setting | | | 0.032 |
| N | 17 | 26 | |
| Mean (SD) | 5.9 (3.5) | 3.6 (3.3) | |
| Median (IQR) | 6.0 (4.0, 8.0) | 3.0 (1.0, 7.0) | |

Abbreviation: IQR, interquartile range.

Bold values show statistically significant p-value.

A combined analysis of participants with HbSS and HbS/βthalassemia did not yield any significant differences in the primary or secondary outcomes between the gabapentin and placebo groups.

### 3.5 Adverse effects

Adverse effects noted in the gabapentin arm included vomiting (n = 2), fatigue (n = 1), pneumonitis (n = 1), itching (n = 1), dizziness (n = 1), and headache (n = 1). Adverse effect in the placebo arm included vomiting (n = 1) and pneumonitis (n = 1). All were grade 1 and no serious adverse effects were noted.

### 4 DISCUSSION

Although neuropathic pain is a known component of VOC, drugs targeting neuropathic pain have not been systematically studied in patients with SCD. Preliminary studies and case reports suggest some efficacy of treatments in reducing the frequency of VOC [37,38].

Our study is the first prospective randomized trial investigating the efficacy of gabapentin during acute VOC pain in SCD. Through a controlled study, we evaluated the utility of adding gabapentin to the standard management of VOC in SCD. A single high dose of gabapentin (15 mg/kg) was chosen for this trial because studies suggest that single high-dose gabapentin can lead to a significant decrease in pain score and opioid consumption [39–43], whereas low-dose gabapentin has limited efficacy [44].

Although the primary endpoint did not reach statistical significance for the entire study cohort, adding gabapentin to standard management of acute VOC for the subgroup of patients with the HbSS genotype resulted in a significantly greater reduction in pain scores from presentation to discharge from acute care setting when compared to the addition of placebo. We did not observe a significant difference between the two study groups for the secondary outcome of opioid consumption. This may be partially related to the fact that the opioid doses were administered using structured dose and time interval guidelines (morphine 0.05–0.1 mg/kg, every 30 min as needed), so access to opioids was standardized for all patients and did not allow the flexibility of self-administration offered by a patient-controlled analgesia design.

Gabapentin use did not influence the rate of hospitalization for the overall study group, as admission rates were similar for both study arms. Nevertheless, among those with the HbSS genotype, the admission rate was higher in the placebo arm than in the gabapentin arm, without reaching statistical significance.

Based on the interim analysis results, and in accordance with the study design, the study team decided to stop enrollment due to clinical futility (i.e., unlikely to meet the primary endpoint even with full accrual). While the study closed early for futility and had only modest efficacy, it is an important study advancing the use of alternative analgesics for acute SCD-related pain.

Some limitations of our study warrant discussion. The study population was small, and our target enrollment was not met due to several challenges common to research in an acute pain setting in patients with SCD. Study enrollment was limited to regular clinic hours and research personnel generally were not available after hours. Participants were allowed enrollment in the study only once. Thus, the overall eligible study population was limited and exhausted after a few years of ongoing study because, in general, the same subgroup of SCD patients tend to have repeated VOC-related visits. Furthermore, only a short time window was allotted for the administration of study drug (i.e., within 1 h of initial opioid administration), which was logistically challenging. Another challenge was obtaining consent from children and young adults who presented in distress, which made eliciting assent from children and consent among those at the age of majority problematic. Occasionally, patients had received opioids and were sleepy before being approached for enrollment. To overcome this, we
worked closely with the IRB to include provisions protecting patients under these circumstances. Approval was obtained to allow candidates 18 years or older to consent via surrogate decision-makers whenever they believed their pain experience or the effects of the pain medications were hindering their ability to give consent independently. An additional challenge was posed by enrollment limited to a single institution, which reduced the patient pool from which the subjects were recruited. Children with SCD have elevated GFR [45]. Thus, they may have lower serum gabapentin serum levels. Therapeutic dose ranges of gabapentin in SCD patients are unknown and sub-therapeutic dosing in our study could have been a possible reason for lack of efficacy.

Our study design was based on the assumption that patients studied had a neuropathic pain component. A better study design may be focused on studying the efficacy of gabapentin in patients with and without neuropathic pain, as determined by clinical neuropathic pain assessment tools such as PainDetect [46]. Overall, our study was a rigorously conducted randomized double-blinded placebo-controlled trial with an objective pain reduction end point. All VOC episodes were treated in a standardized fashion followed with high fidelity.

Gabapentin could be a useful adjunct to standard management for patients with the HbSS genotype, but future studies in a larger cohort of patients with the HbSS genotype and known neuropathic pain might better evaluate gabapentin’s utility. The authors assumed that patients studied had a neuropathic pain component. Future studies should focus on patients with known neuropathic SCD-related pain and compare the efficacy of gabapentin in patients with and without neuropathic pain.

ACKNOWLEDGMENTS
This project was partially supported by a grant from the Scan Design Foundation and ALSAC. The authors thank Cherise Guess, PhD, ELS, for scientific editing support.

AUTHOR CONTRIBUTIONS
Latika Puri, Doralina L. Anghelescu, Kerri Nottage, Jane S. Hankins, Winfred C. Wang, Guolian Kang, and Jeffrey M. Gossett designed the study, analyzed the data, and contributed to the manuscript. Olivia McGregor assisted with study coordination.

CONFLICT OF INTEREST
D.L.A., L.P., W.C.W., G.K., J.M.G., and O.M. have no conflict of interest. J.S.H. receives research support from Global Blood Therapeutics and consultant fees from Global Blood Therapeutics and MJ Lifesciences. K.N. is a Janssen R&D employee and a JNJ stockholder.

ORCID
Latika Puri https://orcid.org/0000-0002-0429-0047

REFERENCES
1. Panepinto JA, Brousseau DC, Hillery CA, Scott JP. Variation in hospitalizations and hospital length of stay in children with vaso-occlusive crises in sickle cell disease. Pediatr Blood Cancer. 2005;44(2):182–6.
2. Tran H, Gupta M, Gupta K. Targeting novel mechanisms of pain in sickle cell disease. Blood. 2017;130(22):2377–85.
3. Brandow AM, Zappia KJ, Stucky CL. Sickle cell disease: a natural model of acute and chronic pain. Pain. 2017;158(Suppl 1):L79–84.
4. Kohli DR, Li Y, Khassabov SG, Gupta P, Kehl LJ, Ericson ME, et al. Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids. Blood. 2010;116(3):456–65.
5. Hillery CA, Kerstein PC, Vilceanu D, Barabas ME, Retherford D, Brandow AM, et al. Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease. Blood. 2011;118(12):3376–83.
6. Wang ZJ, Wilkie DJ, Molokie R. Neurobiological mechanisms of pain in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2010;2010:403–8.
7. Zappia KJ, Garrison SR, Hillery CA, Stucky CL. COLD hypertensitivity increases with age in mice with sickle cell disease. Pain. 2014;155(12):2476–85.
8. Sadler KE, Langer SN, Menzel AD, Moehring F, Erb AN, Brandow AM, et al. Gabapentin alleviates chronic spontaneous pain and acute hypoxia-related pain in a mouse model of sickle cell disease. Br J Haematol. 2019;187(2):246–60.
9. Ezenwa MO, Molokie RE, Wang ZJ, Yao Y, Suarez ML, Pullum C, et al. Safety and utility of quantitative sensory testing among adults with sickle cell disease: indicators of neuropathic pain? Pain Pract. 2016;16(3):282–93.
10. Wilkie DJ, Molokie R, Boyd-Seal D, Suarez ML, Kim YOk, Zong S, et al. Patient-reported outcomes: descriptors of nociceptive and neuropathic pain and barriers to effective pain management in adult outpatients with sickle cell disease. J Natl Med Assoc. 2010;102(1):18–27.
11. Walco GA, Dampier CD. Pain in children and adolescents with sickle cell disease: a descriptive study. J Pediatr Psychol. 1990;15(5):643–58.
12. Brandow AM, Stucky CL, Hillery CA, Hoffmann RG, Panepinto JA. Patients with sickle cell disease have increased sensitivity to cold and heat. Am J Hematol. 2013;88(1):37–43.
13. Jacob E, Chan VW, Hodge C, Zeltzer L, Zurakowski D, Sethna NF. Sensory and thermal quantitative testing in children with sickle cell disease. J Pediatr Hematol Oncol. 2015;37(3):185–9.
14. O’Leary JD, Crawford MW, Odame I, Shorten GD, McGrath PA. Thermal pain and sensory processing in children with sickle cell disease. Clin J Pain. 2014;30(3):244–50.
15. Brandow AM, Farley RA, Panepinto JA. Early insights into the neurobiology of pain in sickle cell disease: a systematic review of the literature. Pediatr Blood Cancer. 2015;62(9):1501–11.
16. Darbari DS, Neely M, van den Anker J, Rana S. Increased clearance of morphine in sickle cell disease: implications for pain management. J Pain. 2011;12(5):531–8.
17. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. Jama. 1998;280(21):1831–6.
18. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280(21):1837–42.
19. van de Vusse AC, Stomp-van den Berg SG, Kessels AH, Weber WE. Randomised controlled trial of gabapentin in complex regional pain syndrome type 1 [ISRCTN84121379]. BMC Neurol. 2004;4:13.
20. Menigaux C, Adam F, Guignard B, Sessler DI, Chauvin M. Preoperative gabapentin decreases anxiety and improves early functional recovery from knee surgery. Anesth Analg. 2005;100(5):1394–9.
21. Fassoulaki A, Patris K, Sarantopoulos C, Hogan Q. The analgesic effect of gabapentin and mexiletine after breast surgery for cancer. Anesth Analg. 2002;95(4):985–91.
22. Rusy LM, Hainsworth KR, Nelson TJ, Czarnecki ML, Tassone JC, Thometz JG, et al. Gabapentin use in pediatric spinal fusion patients: a randomized, double-blind, controlled trial. Anesth Analg. 2010;110(5):1393–8.
23. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42(2):229–36.
24. Taylor CP. The biology and pharmacology of calcium channel alpha2-delta proteins Pfizer satellite symposium to the 2003 Society for Neuroscience Meeting, Sheraton New Orleans Hotel, New Orleans, LA November 10, 2003. CNS Drug Rev. 2004;10(2):183–8.
25. Matthews EA, Dickenson AH. A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy. Anesthesiology. 2002;96(3):633–40.
26. Feng Y, Cui M, Willis WD. Effect of anticonvulsant gabapentin on visceral nociception and its relationship with amino acid neurotransmitters released from spinal cord. Beijing Da Xue Xue Bao Yi Xue Ban. 2003;35(3):307–10.
27. Keskinbora K, Pekel AF, Aydinli I. The use of gabapentin in a 12-year-old boy with cancer pain. Acta Anaesthesiol Scand. 2004;48(5):663–4.
28. Butkovic D, Toljan S, Mihovilovic-Novak B. Experience with gabapentin for neuropathic pain in adolescents: report of five cases. Paediatr Anaesth. 2006;16(3):325–9.
29. Lauder GR, White MC. Neuropathic pain following multilevel surgery in children with cerebral palsy: a case series and review. Paediatr Anaesth. 2005;15(5):412–20.
30. Low AK, Ward K, Wines AP. Pediatric complex regional pain syndrome. J Pediatr Orthop. 2005;15(5):412–20.
31. Nottage KA, Hankins JS, Faughnan LG, James DM, Richardson J, Christiansen R, et al. Addressing challenges of clinical trials in acute pain: the pain management of vaso-occlusive crisis in children and young adults with sickle cell disease study. Clin Trials. 2016;13(4):409–16.
32. Morgan KJ, Angelescu DL. Opioid therapy for pediatric cancer pain. In: Shah RD, Suresh S, editors. Opioid therapy in infants, children, and adolescents. Cham, CH: Springer International Publishing; 2020. p. 251–81.
33. Merkel SI, Veopel-Lewis T, Shayeit T, Malviya S. The FLACC: a behavioral scale for scoring postoperative pain in young children. Pediatr Nurs. 1997;23(3):293–7.
34. Wong DL, Baker CM. Pain in children: comparison of assessment scales. Pediatr Nurs. 1988;14(1):9–17.
35. von Baeyer CL. Children’s self-reports of pain intensity: scale selection, limitations and interpretation. Pain Res Manage. 2006;11(3):157–62.
36. von Baeyer CL, Spagrud LJ, McCormick JC, Choo E, Neville K, Connell MA. Three new datasets supporting use of the numerical rating scale (NRS-11) for children’s self-reports of pain intensity. Pain. 2009;143(3):223–7.
37. Sanders DY, Severance HW, Pollack CV Jr. Sickle cell vaso-occlusive pain crisis in adults: alternative strategies for management in the emergency department. South Med J. 1992;85(8):808–11.
38. Schlaeger JM, Molokie RE, Yao Y, Suarez ML, Golembiewski J, Wilkie DJ, et al. Management of sickle cell pain using pregabalin: a pilot study. Pain Manag Nurs. 2017;18(6):391–400.
39. Seib RK, Paul HE. Preoperative gabapentin for postoperative analgesia: a meta-analysis. Can J Anaesth. 2006;53(5):461–9.
40. Hurley RW, Cohen SP, Williams KA, Rowlingson AJ, Wu CL. The analgesic effects of perioperative gabapentin on postoperative pain: a meta-analysis. Reg Anesth Pain Med. 2006;31(3):237–47.
41. Peng PW, Wijeyasurya DN, Li CC. Use of gabapentin for perioperative pain control—a meta-analysis. Pain Res Manag. 2007;12(2):85–92.
42. Ho KY, Gan TJ, Habib AS. Gabapentin and postoperative pain—a systematic review of randomized controlled trials. Pain. 2006;126(1-3):91–101.
43. Haig GM, Beekbrader HN, Wesche DL, Boellner SW, Ouellet D, Brown RR, et al. Single-dose gabapentin pharmacokinetics and safety in healthy infants and children. J Clin Pharmacol. 2001;41(5):507–14.
44. Straube S, Derry S, Moore RA, Wiffen PJ, McQuay HJ. Single dose oral gabapentin for established acute postoperative pain in adults. Cochrane Database Syst Rev. 2010;2010(5):CD008183.
45. Ataga KI, Derebail VK, Archer DR. The glomerulopathy of sickle cell disease. Am J Hematol. 2014;89(9):907–14.
46. Brandow AM, Farley RA, Panepinto JA. Neuropathic pain in patients with sickle cell disease. Pediatr Blood Cancer. 2014;61(3):512–7.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Puri L, Nottage K, Hankins JS, Wang WC, McGregor O, Gossett JM, et al. Gabapentin for acute pain in sickle cell disease: A randomized double-blinded placebo-controlled phase II clinical trial. eJHaem. 2021;1–8. https://doi.org/10.1002/jha2.188